Nonmelanoma Skin Cancer With Aggressive Subclinical Extension in Immunosuppressed Patients

Primary malignancy in patients with nonmelanoma skin cancer-letter.

Hereditary nonmelanoma skin cancer.

Cutaneous basal and squamous cell carcinomas are among the most frequent malignancies in the white population, with the annual incidence estimates ranging from 1 million to 3.5 million cases in the United States. These tumors can occur either sporadically or in the context of hereditary genodermatoses with cancer predisposition, such as basal cell nevus syndrome, xeroderma pigmentosum, epidermo...

Nonmelanoma skin cancer.

Each year, there are as many cases of nonmelanoma skin cancer as all other cancers combined. Although there is relatively low attributable mortality, the morbidity and expense of treatment is significant. Unlike many other malignancies, host and environmental factors relevant to the pathophysiology have been clearly demonstrated. Surgical ablation remains the mainstay of treatment.

Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery.

BACKGROUND In nonmelanoma skin cancer, the clinically visible portion may represent a small fraction of microscopic tumor spread. Previous studies have examined individual risk factors for subclinical spread based on patient and tumor characteristics. However, these risk factors have not been prioritized or studied in combination. OBJECTIVE To identify the most predictive risk factors for ext...

Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients

The management of lymph nodes in nonmelanoma skin cancer patients is currently still debated. Merkel cell carcinoma (MCC), squamous cell carcinoma (SCC), pigmented epithelioid melanocytoma (PEM), and other rare skin neoplasms have a well-known risk to spread to regional lymph nodes. The use of sentinel lymph node biopsy (SLNB) could be a promising procedure to assess this risk in clinically N0 ...